Eikonoklastes Therapeutics ^Private

Eikonoklastes Therapeutics is an early stage biopharmaceutical company that is dedicated to developing disruptive treatments for neurodegenerative diseases. Their main goal is to rapidly advance innovative medicines for areas of significant unmet medical need. They have acquired their first two assets, including a gene therapy for neurodegenerative diseases and a new generation of tissue factor therapies for cancers with high mortality rates. Their therapies are designed to target specific proteins and receptors involved in the pathology of inflammation and angiogenesis, with the aim of stopping tumor growth and improving patient outcomes. Eikonoklastes Therapeutics is driven by a passion for finding new and better ways to treat diseases and is focused on creating significant value for all stakeholders.